---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-051853"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:46:23.008121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anebulo raises $15M via private placement, FDA supports development of IV selonabant for pediatric cannabis toxicity

## Summary
- Raised $15M gross from sale of 15.2M shares at $0.99/share; change of control as director Aron English now owns >50% of common stock.
- FDA acknowledged unmet need for pediatric cannabis toxicity and proposed close collaboration to efficiently advance IV selonabant program.
- Plans to begin Phase 1 SAD study of IV selonabant in healthy adults in 1H 2025.
- Will modify Loan & Security Agreement with 22NW and JFL Capital: reduce max loan to ~$3M, remove securitization.

## SEC filing metadata
- accession: 0001493152-24-051853
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315224051853/0001493152-24-051853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315224051853/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-051853
- JSON: https://secwatch.observer/filing/0001493152-24-051853.json
- Plain text: https://secwatch.observer/filing/0001493152-24-051853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.